Update – Kalziumstoffwechsel

 

 Buy Article Permissions and Reprints

Abstract

A finely balanced control system keeps the extracellular calcium concentration within narrow limits. Disorders of calcium metabolism are often based on altered parathormone levels. Symptoms are not always clear, sometimes they are even missing: the more it is important to know possible associated diseases. The author presents basics, current diagnostics and concrete therapy options. Central hormone for the regulation of the calcium balance is the parathyroid hormone. With decreasing calcium, PTH leads to an increase in extracellular free calcium concentration in three ways. The classic symptoms of pHPT (polyuria, polydipsia, “stone, leg, and stomach pain”) are rare now, as the condition is diagnosed much earlier. Treatment of choice in all symptomatic patients with pHPT is surgery. FHH and pHPT are both characterized by hypercalcaemia and increased parathyroid hormone. The differential diagnosis of urinary calcium excretion, which is usually lower in FHH but normal or elevated in pHPT, is crucial. In primary hypoparathyroidism, parathyroid failure interferes with calcium homeostasis at a central location. Consequences are hypocalcaemia, hyperphosphatemia and lack of active vitamin D. Due to increased urinary calcium excretion, patients with ADH are at high risk for kidney stones, nephrocalcinosis and the development of renal insufficiency. Recently, rhPTH 1-84 has been available for the treatment of hypoparathyroidism. However, long-term data is still lacking to provide a safe indication, considering potential effects and side effects.

• Literatur

• 1 Jakob F. Kalziumbilanz und systemische Regulationsprinzipien. In: Blum H, Müller-Wieland D. Hrsg. Klinische Pathophysiologie. 10., vollständig überarbeitete und erweiterte Auflage. Stuttgart: Thieme; 2018. DOI: 10.1055/b-004-132250
  Article in Thieme ConnectGoogle Scholar
• 2 Hannan FM, Kallay E, Chang W. et al. The Calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol 2018; 15: 33-51
  PubMedGoogle Scholar
• 3 Bilezikian JP, Bandeira L, Khan A. et al. Hyperparathyroidism. Lancet 2018; 39: 168-178 . doi:10.1016/S0140-6736(17)31430-7
  PubMedGoogle Scholar
• 4 Insogna KL. Primary Hyperparathyroidism. N Engl J Med 2018; 379: 1050-1059
  CrossrefPubMedGoogle Scholar
• 5 Castellano E, Attanasio R, Boriano A. et al. Sex Difference in the Clinical Presentation of Primary Hyperparathyroidism: Influence of Menopausal Status. J Clin Endocrinol Metab 2017; 102: 4148-4152
  CrossrefPubMedGoogle Scholar
• 6 Mayr B, Schnabel D, Dörr HG. et al. Genetics in Endocrinology: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts. Eur J Endocrinol 2016; 174: R189-R208
  CrossrefPubMedGoogle Scholar
• 7 Bilezikian JP, Brandi ML, Eastell R. et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3561-3569
  CrossrefPubMedGoogle Scholar
• 8 Wilhelm SM, Wang TS, Ruan DT. et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg 2016; 151: 959-968
  CrossrefPubMedGoogle Scholar
• 9 Marcocci C, Bollerslev J, Khan AA. et al. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 2014; 99: 3607-3618
  CrossrefPubMedGoogle Scholar
• 10 Peacock M, Bolognese MA, Borofsky M. et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009; 94: 4860-4867
  CrossrefPubMedGoogle Scholar
• 11 Camozzi V, Luisetto G, Basso SM. et al. Treatment of chronic hypercalcemia. Med Chem 2012; 8: 556-563
  PubMedGoogle Scholar
• 12 Tsvetov G, Hirsch D, Shimon I. et al. Thiazide Treatment in Primary Hyperparathyroidism-A New Indication for an Old Medication?. J Clin Endocrinol Metab 2017; 102: 1270-1276
  CrossrefPubMedGoogle Scholar
• 13 Hinnie J, Bell E, McKillop E. et al. The prevalence of familial hypocalciuric hypercalcemia. Calcif Tissue Int 2001; 68: 216-218
  CrossrefPubMedGoogle Scholar
• 14 Christensen SE, Nissen PH, Vestergaard P. et al. Discriminative power of three indices of renal Calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol 2008; 69: 713-720
  CrossrefPubMedGoogle Scholar
• 15 Szczawinska D, Schnabel D, Letz S. et al. A homozygous CaSR mutation causing a FHH phenotype completely masked by vitamin D deficiency presenting as rickets. J Clin Endocrinol Metab 2014; 99: E1146-E1153
  CrossrefPubMedGoogle Scholar
• 16 Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med 2019; 380: 1738-1747
  CrossrefPubMedGoogle Scholar
• 17 Bollerslev J, Rejnmark L, Marcocci C. et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 2015; 173: G1-G20
  CrossrefPubMedGoogle Scholar
• 18 Mannstadt M, Clarke BL, Vokes T. et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 2013; 1: 275-283
  CrossrefPubMedGoogle Scholar
• 19 Rubin MR, Cusano NE, Fan WW. et al. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab 2016; 101: 2742-2750
  CrossrefPubMedGoogle Scholar